Expertise in
32
conditions

Dr. Mahesh K. Seetharam

Mayo Clinic Arizona
Scottsdale, AZ
Expertise in
32
conditions
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
Expertise in
32
conditions
OverviewInsuranceLocationsClinical Research

Overview

Mahesh Seetharam is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Seetharam is highly rated in 32 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Melanoma, Fibrosarcoma, and Bone Marrow Aspiration. Dr. Seetharam is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Sanford Health
  •  Cigna

Locations

MAYO CLINIC ARIZONA
13400 E Shea Blvd, Scottsdale, AZ 85259
480-301-8000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Other, Drug
Study Drugs: Cabozantinib, Temozolomide
Study Phase: Phase 2
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Procedure, Biological, Other, Drug
Study Drugs: Dabrafenib, Navitoclax, Trametinib
Study Phase: Phase 1/Phase 2
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: CYT-0851
Study Phase: Phase 1/Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Procedure, Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 2
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
Enrollment Status: Suspended
Publish Date: February 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: TP-0903
Study Phase: Phase 1
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Biological
Study Drug: BN-Brachyury plus Radiation
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 14 Less Clinical Trials

34 Total Publications

Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
Journal: Melanoma research
Published: August 29, 2024
Similar Doctors
Expertise in
27
conditions
Dr. Tanios S. Bekaii-Saab
Hematology Oncology | Oncology | Hematology
Expertise in
27
conditions
Dr. Tanios S. Bekaii-Saab
Hematology Oncology | Oncology | Hematology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tanios Bekaii-Saab is a Hematologist Oncology specialist and an Oncologist in Scottsdale, Arizona. Dr. Bekaii-Saab is highly rated in 27 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, and Pancreatectomy. Dr. Bekaii-Saab is currently accepting new patients.

Expertise in
16
conditions
Dr. Yousef N. Zakharia
Hematology Oncology | Hematology | Oncology
Expertise in
16
conditions
Dr. Yousef N. Zakharia
Hematology Oncology | Hematology | Oncology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yousef Zakharia is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Zakharia is highly rated in 16 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Melanoma, Bladder Cancer, and Orchiectomy. Dr. Zakharia is currently accepting new patients.

Expertise in
25
conditions
Dr. Madappa N. Kundranda
Hematology | Oncology | Hematology Oncology
Expertise in
25
conditions
Dr. Madappa N. Kundranda
Hematology | Oncology | Hematology Oncology

Banner Cancer Center Specialists LLC

1900 N Higley Rd, 
Gilbert, AZ 
 (14.4 mi)
480-543-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Madappa Kundranda is a Hematologist and an Oncologist in Gilbert, Arizona. Dr. Kundranda is highly rated in 25 conditions, according to our data. His top areas of expertise are Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Kundranda is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile